𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor progression—targets for differential therapy

✍ Scribed by Arthur B. Pardee

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
98 KB
Volume
209
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Differential killing of the patient's cancer cells versus normal cells is a necessity for chemotherapy. Advantage can be taken of close regulations of gene expression and of enzyme activity that are essential for normal cell functioning, and that are altered during tumor progression. Summarized here is our research on four such progression changes of cancer cells; some deregulate proliferation control and others decrease programmed death (apoptosis). These processes will be illustrated with examples of potential chemotherapies based on them. Methods for discovery of such changes include Differential Display and microarrays. J. Cell. Physiol. 209: 589–591, 2006. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Fibronectin as target for tumor therapy
Fibronectin as target for tumor therapy
✍ Manuela Kaspar; Luciano Zardi; Dario Neri 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 347 KB 👁 1 views

During cancer progression, the extracellular matrix (ECM) of the tissue in which the tumor grows is extensively remodeled, both by degradation of preexisting ECM molecules and by the neosynthesis of ECM components, which in many cases are not present in the ECM of normal tissues. Fibronectin (FN), a

Cell cycle: Molecular targets for diagno
Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer
✍ Antonio Giordano; Youcef M. Rustum; Charles E. Wenner 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

A significant portion of published literature is dedicated to describing the cloning and the characterization of proteins involved in the progression of the cell cycle, which govern cell growth both in cancer and normal ontogenesis. With this abundance of information, the cascading pathways of molec

The marine compound spongistatin 1 targe
The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
✍ Andrea S. Rothmeier; Uta M. Schneiders; Romina M. Wiedmann; Ivan Ischenko; Chris 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 788 KB

## Abstract Treatment of pancreatic cancer remains a major challenge and new anticancer drugs are urgently required. Our study presents the marine natural compound spongistatin 1 as a promising experimental drug. Spongistatin 1 was applied in an orthotopic __in vivo__ model of human pancreatic canc

How to overcome (and exploit) tumor hypo
How to overcome (and exploit) tumor hypoxia for targeted gene therapy
✍ Olga Greco; Brian Marples; Michael C. Joiner; Simon D. Scott 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 1 views

## Abstract Tumor hypoxia has long been recognized as a critical issue in oncology. Resistance of hypoxic areas has been shown to affect treatment outcome after radiation, chemotherapy, and surgery in a number of tumor sites. Two main strategies to overcome tumor hypoxia are to increase the deliver

Integrating tumor-initiating cells into
Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy
✍ Keiran S.M. Smalley; Meenhard Herlyn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 144 KB 👁 1 views

## Abstract There is growing evidence to suggest that not all cancer cells have similar levels of malignant potential and that tumor progression may be driven by specialized sub‐sets of “tumor initiating” cells. It is likely that as tumor initiating cells have lower proliferation rates and enhanced